| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GALLMETZER HEALTHCARE Aktie jetzt für 0€ handeln | |||||
| 09:03 | Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY | 237 | EQS Group (EN) | Original-Research: Gallmetzer HealthCare SpA - from NuWays AG
21.09.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible... ► Artikel lesen | |
| 08:55 | Biting into high-margin niches; INITIATE with BUY: Gallmetzer Healthcare combines Gerhò's cash-generative dental distribution ... | 411 | NuWays | Gallmetzer HealthCare (GHC) offers multiple avenues for organic growth and margin expansion. The company is a vertically integrated dental healthcare platform combining a resilient, cash-generative... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BILLIONTOONE | 105,92 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| PROGYNY | 27,130 | 0,00 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| MIMEDX | 4,770 | 0,00 % | Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8 | ||
| BRIGHTSPRING HEALTH SERVICES | 56,76 | 0,00 % | Here's Why You Should Add BrightSpring Stock to Your Portfolio Now | ||
| BETA BIONICS | 21,890 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its... ► Artikel lesen | |
| HEARTFLOW | 50,65 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,335 | 0,00 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| ANTERIS TECHNOLOGIES GLOBAL | 8,160 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Compensatory Arrangements of Certain Officers | ||
| LIFESTANCE HEALTH GROUP | 12,575 | 0,00 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| AVEANNA HEALTHCARE | 13,655 | 0,00 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| FRESENIUS | 45,670 | -0,42 % | BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Fresenius mit einem Kursziel von 57,50 Euro auf "Overweight" belassen. Die Veränderungsrate, wesentlicher Parameter... ► Artikel lesen | |
| GENEDX | 101,09 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| CONCENTRA GROUP | 35,420 | 0,00 % | Concentra Names Tanner Newton As Chief Financial Officer | ||
| PRIVIA HEALTH GROUP | 19,840 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,210 | -0,79 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |